RTTNews | Jan 24, 2022 11:57AM EST

11:57 Monday, January 24, 2022 (RTTNews.com) - Shares of SELLAS Life Sciences Group, Inc. (SLS) slipped nearly 14% on Monday morning despite no stock-related news from the company to hurt the shares.

SLS is currently trading at $4.3550, down $0.7150 or 14.1026%, on the Nasdaq.

SELLAS Life Sciences Group is a late-stage biopharmaceutical company that is focused on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.

Read the original article on RTTNews ( https://www.rttnews.com/3256777/sellas-life-sciences-stock-down-14.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved